In this episode, TRC Healthcare editor, Rachel Cole, PharmD, delves into the debate about whether newer medications for Type 2 diabetes, including SGLT-2 inhibitors or GLP-1 agonists, should be used first-line instead of metformin. She examines the benefitsand drawbacks of these newer medications, including their cardiovascular and kidney benefits, side effects, and costs.

This is an excerpt from our March 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:

• Article: Stay Current on Med Recommendations for Diabetes
• Algorithm: Stepwise Treatment of Type 2 Diabetes
• Chart: Diabetes Medications: Cardiovascular and Kidney Impact
• Resource Hub: Diabetes

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools.

Use code podcast1025 at checkout for 10% off a new subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

Send us a text

****

Join the National Community Pharmacists Associations’ Annual Convention (NCPA) in New Orleans October 18-21st: https://bit.ly/ncpameeting25

****

If you’re not yet a subscriber, find out more about our product offerings at trchealthcare.com.

Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.